Gelified ethanol for percutaneous sclerotherapy of bone lesions: a systematic review of clinical applications and outcomes.

Skeletal RadiolMay 22, 2026 (epub)
Clinical ResearchRadiology (Diagnostic)Orthopedic SurgeryOpen access

Sylvain Grange, Laura-Cristina Morales Cifuentes, Rémi Grange et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the safety and effectiveness of radiopaque gelified ethanol (RGE) sclerotherapy for bone lesions, analyzing six retrospective studies involving 55 patients. The study found a technical success rate of 100%, with 64.3% of patients experiencing complete pain resolution. The review highlights RGE as a promising minimally invasive treatment for benign bone lesions.

Key findings

  • Technical success was reported in 100% of procedures.
  • Complete pain resolution occurred in 64.3% of patients.
  • Radiological follow-up showed a complete response in 96% of lesions.
  • Subsequent surgery was required in 3.6% of lesions.

Why it matters

Understanding the effectiveness and safety of RGE sclerotherapy can inform clinical decision-making for treating benign bone lesions, potentially offering a minimally invasive alternative to more invasive surgical options.

Source

PubMed · PMID 42174179Free full text on PubMed Central

Published in Skeletal Radiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Radiology (Diagnostic)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.